Editas Medicine, Inc. Income Statement
EDIT|8 years of annual SEC 10-K data (FY2018-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 8 fiscal years. All figures from audited SEC 10-K filings.
Editas Medicine, Inc. reported $32M in revenue and $237M in net loss for FY2025. Revenue has grown at a 27.0% compound annual rate over the past 7 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $32.3M | $19.7M | $25.5M | $90.7M | $20.5M | $31.9M | $13.7M | $6.1M |
| SG&A Expense | $72.0M | $70.7M | $76.2M | $67.6M | $64.6M | $55.0M | $50.5M | $46.3M |
| R&D Expense | $199.2M | $175.0M | $142.5M | $158.0M | $96.9M | $90.7M | $83.2M | $57.0M |
| Operating Income | -$251.2M | -$225.9M | -$193.1M | -$134.8M | -$140.9M | -$113.7M | -$119.9M | -$97.2M |
| Interest Expense | $2.2M | $2.1M | - | - | - | - | - | - |
| Income Tax | $0 | $0 | $0 | $0 | - | - | - | - |
| Net Income | -$237.1M | -$220.4M | -$192.5M | -$116.0M | -$133.7M | -$110.0M | -$120.3M | -$97.2M |
| EPS (Basic) | -$2.88 | -$3.21 | -$2.85 | -$1.98 | -$2.68 | $0.13 | - | - |
| EPS (Diluted) | -$2.88 | -$3.21 | -$2.85 | -$1.98 | -$2.68 | $0.12 | -$2.98 | -$3.02 |
| Shares Outstanding | 82.7M | 81.8M | 68.8M | 68.4M | 62.6M | 54.4M | 48.8M | 44.5M |
| Operating Margin | -777.2% | -1146.3% | -756.1% | -148.6% | -686.4% | -356.1% | -873.6% | -1605.6% |
| Profit Margin | -733.7% | -1118.3% | -753.6% | -127.8% | -651.4% | -344.3% | -876.5% | -1605.5% |